MetaCap

Adlai Nortye Group (ANL) vs Zevra Therapeutics (ZVRA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Adlai Nortye Group (ANL) has outperformed Zevra Therapeutics (ZVRA) over the past year, gaining 533.3% versus a gain of 1.9%. Adlai Nortye Group is the larger company by market cap ($550.6 million vs $521.3 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ANL+533.33%ZVRA+1.86%
+1188%+547%-93%
Nov 21, 20251 yearNov 20, 2026
ANL-43.00%ZVRA+81.74%
+204%+48%-107%
Sep 25, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ANL versus ZVRA key metrics
MetricANLZVRA
Share price$8.55$8.76
Market cap$550.60M$521.26M
1-day change-5.63%-3.42%
YTD return+502.11%-2.23%
1-year return+533.33%+1.86%
5-year return—+8.82%
P/E ratio (TTM)—7.18
Forward P/E—9.84
EPS (TTM)$-0.66$1.22
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$106.47M
Revenue growth (YoY)—+350.91%
Net income (latest FY)$-51.87M$83.23M
Gross margin—84.52%
Operating margin—-59.12%
Net margin—78.17%
52-week high$17.25$15.04
52-week low$0.879$8.01
Distance from 52-week high-50.43%-41.74%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+245.03%+162.56%
Average volume244.74K954.53K
Shares outstanding58.73M59.50M
Employees10961
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ANL has outperformed ZVRA by 531.5 percentage points over the past year.

About Adlai Nortye Group

ANL stock →

Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies.

Health Care · Biotechnology: Pharmaceutical Preparations · 109 employees

About Zevra Therapeutics

ZVRA stock →

Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform.

Health Care · Biotechnology: Pharmaceutical Preparations · 61 employees

ANL vs ZVRA FAQ

Which is bigger, Adlai Nortye Group or Zevra Therapeutics?

Adlai Nortye Group (ANL) is larger, with a market capitalization of $550.60M compared with $521.26M for Zevra Therapeutics (ZVRA).

Which stock has performed better over the past year, ANL or ZVRA?

ANL returned +533.33% over the past 12 months, compared with +1.86% for ZVRA (price return, excluding dividends). Past performance does not predict future results.

Are Adlai Nortye Group and Zevra Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons